Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue S1, 2015, Pages 78-84

  Kohler, Ilona ^a   Bronsert, Peter ^a,b   Timme, Sylvia ^a   Werner, Martin ^a,b,c   Brabletz, Thomas ^a,b,c   Hopt, Ulrich Theodor ^a   Schilling, Oliver ^b   Bausch, Dirk ^d   Keck, Tobias ^d   Wellner, Ulrich Friedrich ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

E Cadherin; Epithelial mesenchymal transition; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Pancreatoduodenectomy; Tumor budding

Indexed keywords

BETA CATENIN; CYTOKERATIN; UVOMORULIN; VIMENTIN; CADHERIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; LYMPH NODE RATIO; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS ADENOCARCINOMA; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; STAINING; TISSUE SLICE; TUMOR INVASION; ANALYSIS OF VARIANCE; CELL TRANSFORMATION; DISEASE COURSE; FORECASTING; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CADHERINS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FORECASTING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84925955019     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12752     Document Type: Article

References (44)

1. He J, Ahuja N, Makary MA etal. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford) 2013; 16(1): 83-90.
2. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann. Surg. 2006; 244: 10-15.
3. Fernández-Del Castillo C, Morales-Oyarvide V, McGrath D etal. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery 2012; 152 (3 Suppl. 1): S56-63.
4. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008; 9: 99-132.
5. Franko J, Hugec V, Lopes TL, Goldman CD. Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer <1 or 2cm. Ann. Surg. Oncol. 2013; 20: 357-361.
6. Ferrone CR, Pieretti-Vanmarcke R, Bloom JP etal. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 2012; 152 (3 Suppl. 1): S43-49.
7. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J. Surg. Oncol. 2012; 107(1): 15-22.
8. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
9. Brabletz T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 2012; 12: 425-436.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
11. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005; 5: 744-749.
12. Mani SA, Guo W, Liao MJ etal. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
13. Wellner U, Schubert J, Burk UC etal. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009; 11: 1487-1495.
14. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis. Colon Rectum 1993; 36: 627-635.
15. Karamitopoulou E. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front. Oncol. 2012; 2: 1-5.
16. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br. J. Cancer 2012; 106: 1713-1717.
17. Ohike N, Coban I, Kim GE etal. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am. J. Surg. Pathol. 2010; 34: 1417-1424.
18. Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z. The prognostic value of tumor budding in invasive breast cancer. Pathol. Res. Pract. 2013; 209: 269-275.
19. Taira T, Ishii G, Nagai K etal. Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. Lung Cancer 2012; 76: 423-430.
20. Karamitopoulou E, Zlobec I, Born D etal. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur. J. Cancer 2012; 49(5): 1032-1039.
21. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumors of the Digestive System, 4th edn. Lyon: International Agency for Research in Cancer, 2010.
22. Hamilton S, Aaltonen L. Pathology and Genetics and Pathology of Tumors of the Digestive System, 1st edn. Lyon: International Agency for Research in Cancer, 2000.
23. Broders A. Squamous-cell epithelioma of the lip: a study of five hundred and thirty-seven cases. J. Am. Med. Assoc. 1920; 74: 656-664.
24. Wright JR Jr. Albert C. Broders' paradigm shifts involving the prognostication and definition of cancer. Arch. Pathol. Lab. Med. 2012; 136: 1437-1446.
25. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50: 151-162.
26. Winter JM, Brennan MF, Tang LH etal. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann. Surg. Oncol. 2012; 19: 169-175.
27. Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann. Surg. 2004; 240: 293-298.
28. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008; 68: 3645-3654.
29. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009; 119: 1420-1428.
30. Guilford P, Hopkins J, Harraway J etal. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405.
31. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009; 28: 151-166.
32. Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical wnt signaling. Cold Spring Harb. Perspect. Biol. 2010; 2: a002915.
33. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 2012; 142: 219-232.
34. Brabletz T, Jung A, Reu S etal. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl Acad. Sci. U.S.A. 2001; 98: 10356-10361.
35. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006; 66: 8319-8326.
36. Esposito I, Kleeff J, Bergmann F etal. Most pancreatic cancer resections are R1 resections. Ann. Surg. Oncol. 2008; 15: 1651-1660.
37. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 2009; 11: 18-24.
38. Thomas RM, Truty MJ, Nogueras-Gonzalez GM etal. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J. Gastrointest. Surg. 2012; 16: 1696-1704.
39. Gleisner AL, Assumpcao L, Cameron JL etal. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007; 110: 2484-2492.
40. Michalski CW, Erkan M, Hüser N etal. Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig. Surg. 2008; 25: 473-480.
41. Seelig SK, Burkert B, Chromik AM, Tannapfel A, Uhl W, Seelig MH. Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy. HPB Surg. [Internet] 2010; 2010: 1-6. Cited 9 Sep 2013. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010622/
42. Klein F, Puhl G, Guckelberger O etal. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol. Res. Pract. [Internet] 2012; 2012: 1-8. Cited 9 Sep 2013. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508736/
43. Strobel O, Hartwig W, Hackert T etal. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann. Surg. Oncol. 2013; 20: 964-972.
44. Strobel O, Hackert T, Hartwig W etal. Survival data justifies resection for pancreatic metastases. Ann. Surg. Oncol. 2009; 16: 3340-3349.